Persistent URL of this record https://hdl.handle.net/1887/3276570
Documents
-
- Download
- oncolo_26_11_e2053
- Publisher's Version
-
open access
- Full text at publishers site
In Collections
This item can be found in the following collections:
Clinical benefit of ripretinib dose escalation after disease progression in advanced gastrointestinal stromal tumor: an analysis of the INVICTUS study
- All authors
- Zalcberg, J.R.; Heinrich, M.C.; George, S.; Bauer, S.; Schoffski, P.; Serrano, C.; Gelderblom, H.; Jones, R.L.; Attia, S.; D'Amato, G.; Chi, P.; Reichardt, P.; Somaiah, N.; Meade, J.; Reichert, V.; Shi, K.; Sherman, M.L.; Ruiz-Soto, R.; Mehren, M. von; Blay, J.Y.
- Date
- 2021-08-16
- Journal
- The Oncologist
- Volume
- 26
- Issue
- 11
- Pages
- E2053 - E2060